TCI Wealth Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

TCI Wealth Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3	Closed	-$26	–	423
2023 Q1	$26	Sell	3 -430	-99%	-$4.14K	﹤0.01%	2476
2022 Q4	$4.97K	Sell	433 -3	-0.7%	-$37	﹤0.01%	1528
2022 Q3	$5K	Buy	436 +6	+1%	+$77	﹤0.01%	1425
2022 Q2	$5K	Sell	430 -381	-47%	-$3.93K	﹤0.01%	1444
2022 Q1	$13K	Hold	811	–	–	﹤0.01%	914
2021 Q4	$11K	Buy	811 +177	+28%	+$2.34K	﹤0.01%	1072
2021 Q3	$9K	Buy	634 +487	+331%	+$7.68K	﹤0.01%	1142
2021 Q2	$2K	Sell	147 -51	-26%	-$693	﹤0.01%	1954
2021 Q1	$2K	Buy	+198	New	+$2.04K	﹤0.01%	1673

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

TCI Wealth Advisors's BCRX Position: Q2 2023 in Review

TCI Wealth Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2023, closing a stake of 3 shares — an estimated $26 sold.

TCI Wealth Advisors first reported a position in BCRX in Q1 2021 and held it in 9 quarters. The position peaked at $13K in Q1 2022. 236 funds tracked by Wall St. Rank hold BCRX as of Q2 2023.

TCI Wealth Advisors reported no remaining BioCryst Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
TCI Wealth Advisors sold 3 BioCryst Pharmaceuticals shares in Q2 2023, an estimated $26.
TCI Wealth Advisors first reported a position in BioCryst Pharmaceuticals in Q1 2021 and held it in 9 quarters.
TCI Wealth Advisors's BioCryst Pharmaceuticals position peaked at $13K in Q1 2022.
236 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.